Stifel Maintains Buy on Tandem Diabetes Care, Raises Price Target to $55
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Mathew Blackman maintains a Buy rating on Tandem Diabetes Care (NASDAQ:TNDM) and raises the price target from $45 to $55.
May 22, 2024 | 11:21 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Mathew Blackman has maintained a Buy rating on Tandem Diabetes Care and increased the price target from $45 to $55.
The Buy rating and increased price target from a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100